<DOC>
	<DOCNO>NCT01944735</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multiple oral dos CTX-4430 administer cystic fibrosis ( CF ) patient once-daily ( QD ) 15 days.This study include two dose level . For dose level , blood sample collect exploratory PK PD assay validation . In addition , sputum collect exploratory biomarker analysis . Following multiple dose administration , pulmonary function exploratory lung clearance index ( LCI ) measurements take .</brief_summary>
	<brief_title>Phase 1 Study Assessing Safety Tolerability CTX-4430 Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>1 . Adult male female , 18 55 year age ( inclusive ) time screen . 2 . Confirmed diagnosis CF base following : positive sweat chloride sodium value ≥ 60 mEq/L , and/or genotype two identifiable mutation consistent CF , accompany one clinical feature consistent CF phenotype diagnosis CF make specialist condition . 3 . In judgment Principal Investigator ( PI ) , patient medically stable change symptom , medication , clinical laboratory result PI opinion compatible diagnosis either CF complication thereof judge acceptable inclusion . 4 . Body mass index ( BMI ) ≥ 17.0 ( kg/m2 ) . 5 . Nontobacco/nicotinecontaining product user minimum 6 month prior first study drug administration . 6 . Forced Expiratory Volume ( FEV1 ) &gt; 50 % &lt; 90 % predict screening . 7 . Must agree use adequate method contraception . 1 . Patient display significant clinical/laboratory/radiological/spirometric sign unstable unexpectedly deteriorate respiratory disease within 30 day prior first study drug administration . 2 . History presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease depart patient 's usual baseline level health patient CF . 3 . Has history lung transplantation . 4 . History presence alcoholism drug abuse within 2 year prior first study drug administration . 5 . Personal family history prolong QT syndrome ; QTc interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) use Bazett 's formula ( QTcB ) deem clinically significant PI . 6 . Sitting blood pressure le 90/40 mmHg great 140/90 mmHg , unless deem clinically insignificant PI . 7 . Pulse high 100 b.p.m low 50 b.p.m . unless deem clinically insignificant PI . 8 . Failure satisfy PI fitness participate reason . 9 . In judgment PI , clinically significant hemoptysis ( &gt; 30 cc per episode ) within last 180 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>